Phencyclidine binding sites in the nucleus accumbens and phencyclidine-induced hyperactivity are decreased following lesions of the mesolimbic dopamine system.
[3H]Phencyclidine [( 3H]PCP) binding to rat nucleus accumbens, hippocampal and striatal membranes, and PCP-induced locomotor hyperactivity were assessed following selective lesions of the mesolimbic dopaminergic system. 6-Hydroxydopamine (6-OHDA) injections into the A10 region of the ventral tegmental area or into the accumbens itself resulted in a blockade of PCP's stimulatory effects and a highly significant reduction in the number of [3H]PCP binding sites and dopamine content of the nucleus accumbens. However, destruction of the dopaminergic mesolimbic fibers did not significantly alter hippocampal or striatal [3H]PCP binding. The data suggest that PCP elicits its locomotor stimulating effects via an interaction with PCP binding sites located mostly on mesolimbic dopaminergic terminals within the nucleus accumbens.
D000818:Animals; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D006892:Hydroxydopamines / Q000494:pharmacology; D008032:Limbic System / Q000378:metabolism*; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D009714:Nucleus Accumbens / Q000378:metabolism*; D016627:Oxidopamine; D010622:Phencyclidine / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D017981:Receptors, Neurotransmitter / Q000378:metabolism*; D017478:Receptors, Phencyclidine; D012686:Septal Nuclei / Q000378:metabolism*; D013997:Time Factors
D006892:Hydroxydopamines; D017981:Receptors, Neurotransmitter; D017478:Receptors, Phencyclidine; D016627:Oxidopamine; D010622:Phencyclidine; D004298:Dopamine